thymalfasin raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2026-03-12. Anything still debated is marked as such rather than presented as settled.
The peptide was identified during work in the 1970s on thymosin fraction 5, a partially purified extract of calf thymus. Investigators separated that mixture and characterized individual components, one of which they named thymosin alpha-1. The same compound later received the international nonproprietary name thymalfasin. Commercial material is produced by solid-phase peptide synthesis rather than by extraction, so synthetic and natural forms share an identical sequence. Naming conventions vary across the literature, and readers should distinguish the alpha-1 peptide from other thymosins that have unrelated sequences and functions.
Thymosin beta-4 is a separate 43-residue peptide that binds actin and participates in cell migration; it shares no sequence similarity with thymosin alpha-1 despite the common family name. Other preparative materials, such as thymosin fraction 5 and thymopoietin, contain distinct mixtures or peptides. The shared thymosin label reflects the tissue of origin used in early purification, not a common structural core. Treating these molecules as interchangeable is a frequent source of confusion in laboratory reports and in popular summaries alike.
Quality control for thymosin alpha-1 focuses on identity, purity, and potency. Identity is confirmed by mass spectrometry and amino acid analysis, while purity is assessed by chromatography with limits on related substances and residual solvents. Potency assays may use cell-based immune readouts, but these are not standardized across laboratories. Regulatory status differs by jurisdiction; no product is approved in the United States for clinical use, whereas some other countries register injectable forms for specific indications.
Quantifying thymosin alpha-1 in a sample usually relies on reverse-phase high-performance liquid chromatography. The peptide lacks strong chromophores, so detection often occurs at 214 nm, where the peptide backbone absorbs. Mass spectrometry provides confirmatory identification and can detect sequence variants or truncations. Immunoassays have been used in biological matrices, but they may cross-react with related fragments. For purity assessment, chromatographic peak area gives the main component percentage, while mass accuracy verifies molecular identity.
| Property | Value | Notes |
|---|---|---|
| Molecular mass | About 3.1 kDa | 28 residues, N-terminally acetylated |
| Appearance | White to off-white powder | Lyophilized solid |
| Solubility | Freely soluble in water | Also soluble in aqueous buffers |
| Storage temperature | 2 to 8 °C | Protect from light and moisture |
| Common synonyms | Thymalfasin; Tα1 | Same peptide sequence |
Whether the free 28-residue peptide circulates in human tissue remains debated. The best-documented human source is prothymosin alpha, a larger acidic protein that carries the sequence at its N-terminus. Reports of measurable peptide levels in serum and lymphoid tissue exist, yet some of that signal may come from cross-reacting fragments or from the parent protein. Most reviews therefore treat prothymosin alpha as the established human molecule and describe independent circulation of the small peptide as an unresolved question.
Immunological studies connect the peptide to multiple parts of the immune response. It has been reported to engage Toll-like receptor signaling, to promote dendritic cell maturation, and to influence the balance of T helper cell subsets. Changes in natural killer cell activity and in cytokine release appear in cell culture and animal models. These observations describe broad immunomodulatory behavior rather than a single defined receptor target, and the primary molecular interaction has not been settled.
The lyophilized peptide is a white to off-white powder that dissolves freely in water and in aqueous buffers near neutral pH. Because the molecule carries a net negative charge under physiological conditions, saline and phosphate solutions are the usual vehicles, while strongly acidic media are avoided. Stock solutions are commonly divided into small aliquots so that repeated freezing and thawing can be limited, since cycling may encourage aggregation. Solubility in organic solvents is poor and those solvents are seldom used as primary diluents.
Recommended storage for the dry powder is a freezer near minus twenty degrees Celsius, kept desiccated and away from light. Once dissolved, the peptide is less stable and is usually held at two to eight degrees Celsius for short intervals or frozen for longer storage. Stability studies focus on the acetylated terminus and the disulfide linkage because those features define the intact molecule. Common degradation routes include cysteine oxidation, deamidation of asparagine or glutamine side chains, and slow formation of higher-molecular-weight species.
Clinical research has examined the peptide in chronic hepatitis B and C, as a vaccine adjuvant, and in sepsis and oncology settings. Findings across trials are mixed; some report changes in selected immune markers, while others find no clear clinical benefit. Many studies are small and define outcomes differently, which limits comparison. Regulatory approval is confined to a few countries, and the compound is not an approved drug in the United States or most of Europe.
Overall evidence quality varies considerably. A large share of published reports come from single centers, rely on surrogate immunological markers, or lack adequate control groups. Systematic reviews have highlighted this heterogeneity as a barrier to pooling results. Open questions include which patients, if any, might benefit, what treatment duration is appropriate, and whether any effect is independent of standard care. The peptide is often described as an immune modulator rather than a therapy for one disease, which complicates confirmatory trial design.
Thymosin alpha 1 was identified in 1977 as a component of thymosin fraction 5, a heterogeneous preparation used in early studies of thymic function. Investigators purified the active material and determined its amino acid sequence, which enabled chemical synthesis. Work in the following decades concentrated on T-cell maturation and immune reconstitution in animals and small human cohorts. Early preparations varied in composition, so results from that period are difficult to compare with studies using defined synthetic peptide.
== Genetics == The gene affected is the DMD gene, is located on the X chromosome and is inherited in an X-linked recessive pattern. Since women have two X chromosomes, if one X chromosome has the non-working gene, the second X chromosome will have a working copy of the gene to compensate, because of this ability to compensate, women rarely develop symptoms. All dystrophinopathies are inherited in an X-linked recessive manner. The risk to the siblings of an affected individual depends upon the carrier status of the mother. Carrier females have a 50% chance of passing the DMD mutation in each pregnancy. Sons who inherit the mutation will be affected; daughters who inherit the mutation will be carriers. Men who have Becker muscular dystrophy can have children, and all their daughters are carriers, but none of the sons will inherit their father's mutation. The DMD gene can be broken down into four different regions: the N terminal, rod, cysteine-rich, and carboxy terminal. This is the largest gene/protein in the human body, and due to its size, can have many different mutations affecting it and therefore differing clinical presentations. For example some patients with Becker's can be asymptomatic aside from blood work abnormalities, and some can present with progressive muscle weakness, heart defects, and difficulty with activities of daily living.
==== Albums ==== Butterfly Love (Boner Records, 1989) Lurch (Boner Records, 1990) Tulip (Boner Records, 1990) The Miracle of Sound in Motion (Boner Records, 1993) Your Choice Live Series 019 (Your Choice Records, 1993) Best of Steel Pole Bathtub (Sento, 1993) Scars from Falling Down (Slash/London, 1995) Unlistenable (Zero to One, 2002)
Philippine Leroy-Beaulieu (French pronunciation: [filipin ləʁwa boljø]; born 25 April 1963) is a French actress. She is the daughter of actor Philippe Leroy and model Françoise Laurent. She made her screen debut in the 1983 comedy-drama film Surprise Party, before starring in the 1985 comedy film Three Men and a Cradle. She received a nomination for the César Award for Most Promising Actress for the latter role. Leroy-Beaulieu has played leading and supporting roles in more than 50 movies. In recent years, she played the title character in the RTBF crime comedy series Agathe Koltès (2016–2019); in 2020 she began starring as Sylvie Grateau in the Netflix comedy-drama series Emily in Paris.
Tetrahydrobiopterin (branded as Kuvan) (sapropterin dihydrochloride), a small molecule drug for phenylketonuria, introduced in 2007 as the first medication-based intervention to treat phenylketonuria Arylsulfatase B (branded as Naglazyme) (galsulfase), a recombinant protein therapeutic for Maroteaux–Lamy syndrome (also called mucopolysaccharidosis type VI) Iduronidase (branded as Aldurazyme), a recombinant protein therapeutic for mucopolysaccharidosis I Amifampridine (branded as Firdapse), a small molecule drug for Lambert–Eaton myasthenic syndrome (as of 2013 approved in the EU only) Elosulfase alfa (branded as Vimizim), is the only enzyme replacement therapy to address the cause of Morquio A Syndrome (MPS IVA), which affects an estimated 3,000 patients in the developed world. The disease occurs as a result of a deficiency of activity in an enzyme involved in glycosaminoglycan (GAG) metabolism. Cerliponase alfa (branded as Brineura), is an enzyme replacement treatment for Batten disease, which is a form of neuronal ceroid lipofuscinosis. It was approved in 2017. Valoctocogene roxaparvovec (branded as Roctavian) is an adeno-associated viral vector for treatment of hemophilia A that aims to transfer a working copy of the Factor VIII gene into patients who lack one. It was approved in the EU in August 2022. Biomarin is working to develop several new drugs.
The Fascist regime in Italy put an end to the social unrest, banning trade unions and jailing socialist leaders, notably Antonio Gramsci. On the other hand, Benito Mussolini largely subsidised the automotive industry, in order to provide vehicles to the army. Turin was a target of Allied strategic bombing during World War II, being heavily damaged by the air raids in its industrial areas as well as in the city centre. Along with Milan, Genoa, and La Spezia, Turin was one of Italy's four cities that suffered area bombing by the RAF; the heaviest raid took place on 13 July 1943, when 295 bombers dropped 763 tons of bombs, killing 792 people. Overall, these raids killed 2,069 inhabitants of Turin, and destroyed or damaged 54% of all buildings in the city. In March 1943 the city's factories were the starting point of the first mass strikes in Fascist Italy. The Allies' campaign in Italy started from the south and slowly moved northwards in the following two years. The northern regions were occupied by Germans and collaborationist forces for several years. Turin was not captured by the Allies until the end of the Spring Offensive of 1945. By the time the vanguard of the armoured reconnaissance units of the Brazilian Expeditionary Force reached the city, it was already freed by the Italian Partisans. They had begun revolting against the Germans and the Italian RSI troops on 25 April 1945. Days later, troops from the US Army's 1st Armored and 92nd Infantry Divisions came to substitute for the Brazilians. In the postwar years, Turin was rapidly rebuilt.
Sources: en.wikipedia.org
Philip wrote a contract giving Tessa half of all the rights to the novel, which stated that Tessa "participated to a great extent in writing the outline and novel A Scanner Darkly with me, and I owe her one half of all income derived from it". There was also the challenge of transmuting the events into "science fiction", as Dick felt that he could not sell a mainstream or literary novel after several previous failures. Providing invaluable aid in this field was Judy-Lynn del Rey, head of Ballantine Books' SF division, which had optioned the book. Del Rey suggested the timeline change to 1994 and emphasized the more futuristic elements of the novel, such as the "scramble suit" employed by Fred (which, incidentally, emerged from one of the mystical experiences). Yet much of the dialogue spoken by the characters used hippie slang, dating the events of the novel to their "true" time-frame of 1970–72. Upon its publication in 1977, A Scanner Darkly was hailed by ALA Booklist as "his best yet!" Brian Aldiss lauded it as "the best book of the year", while Robert Silverberg praised the novel as "a masterpiece of sorts, full of demonic intensity", but concluded that "it happens also not to be a very successful novel... a failure, but a stunning failure". Spider Robinson panned the novel as "sometimes fascinating, sometimes hilarious, [but] usually deadly boring". Sales were typical for the SF genre in America, but hardcover editions were issued in Europe, where all of Dick's works were warmly received.
A low RDW has no clinical significance, but an elevated RDW represents increased variation in red blood cell size, a condition known as anisocytosis. Anisocytosis is common in nutritional anemias such as iron deficiency anemia and anemia due to vitamin B12 or folate deficiency, while people with thalassemia may have a normal RDW. Based on the CBC results, further steps can be taken to investigate anemia, such as a ferritin test to confirm the presence of iron deficiency, or hemoglobin electrophoresis to diagnose a hemoglobinopathy such as thalassemia or sickle cell disease.
== Research == In one clinical study, pentazocine was found to rapidly and substantially reduce symptoms of mania in individuals with bipolar disorder that were in the manic phase of the condition. It was postulated that the efficacy observed was due to κ-opioid receptor activation-mediated amelioration of hyperdopaminergia in the reward pathways. Minimal sedation and no side effects including psychotomimetic effects or worsening of psychosis were observed at the dose administered.
PKPD modeling (pharmacokinetic pharmacodynamic modeling) (alternatively abbreviated as PK/PD or PK-PD modeling) is a technique that combines the two classical pharmacologic disciplines of pharmacokinetics and pharmacodynamics. It integrates a pharmacokinetic and a pharmacodynamic model component into one set of mathematical expressions that allows the description of the time course of effect intensity in response to administration of a drug dose. PKPD modeling is related to the field of pharmacometrics. Central to PKPD models is the concentration-effect or exposure-response relationship. A variety of PKPD modeling approaches exist to describe exposure-response relationships. PKPD relationships can be described by simple equations such as linear model, Emax model or sigmoid Emax model. However, if a delay is observed between the drug administration and the drug effect, a temporal dissociation needs to be taken into account and more complex models exist:
Sources: en.wikipedia.org
=== Stability === An important role for proprioception is to allow an animal to stabilize itself against perturbations. For instance, for a person to walk or stand upright, they must continuously monitor their posture and adjust muscle activity as needed to provide balance. Similarly, when walking on unfamiliar terrain, or even tripping, the person must adjust the output of their muscles quickly based on estimated limb position and velocity. Proprioceptor reflex circuits are thought to play an important role to allow fast and unconscious execution of these behaviors. To make control of these behaviors efficient, proprioceptors are also thought to regulate reciprocal inhibition in muscles, leading to agonist-antagonist muscle pairs.
medical physicists and biochemists) for medical research projects, but it is becoming clear that it also has the ability to give doctors useful clinical information, especially with the discovery that it can be used to probe the concentration of alpha-Hydroxyglutaric acid, which is only present in IDH1 and IDH2 mutated gliomas, which alters the prescribed treatment regimen. MRS is currently used to investigate a number of diseases in the human body, most notably cancer (in brain, breast and prostate), epilepsy, Alzheimer's disease, Parkinson's disease, and Huntington's chorea. MRS has been used to diagnose pituitary tuberculosis. Prostate cancer: Combined with a magnetic resonance imaging (MRI) and given equal results, then the three-dimensional MRS can predict the prevalence of a malignant degeneration of prostate tissue by approximately 90%. The combination of both methods may be helpful in the planning of biopsies and therapies of the prostate, as well as to monitor the success of a therapy.
Tel Yavne was first excavated in 2005 in a dig headed by Dan Bahat, who unearthed the gate room of the Crusader castle of Ibelin, as well as a vault destroyed with gunpowder by the Mamluks and deeply embedded Crusader walls east of it, all at or around the top of the tell. In December 2019, a large number of pottery kilns and 1,200-year-old gold coins which may have been a local potter's "piggy bank" were unearthed in a juglet by the Israel Antiquities Authority. According to archaeologist Robert Kool, the coins date back to the early Abbasid period, about 9th century CE. One of the seven coins was minted by Caliph Harun al-Rashid (786–809 CE). "These are gold dinars issued by the Aghlabid dynasty that ruled in North Africa. Without a doubt this is a wonderful Hanukkah present for us," said Kool. In August 2020, Israeli archaeologists discovered 425 complete gold coins, most dating to the Abbasid period around 1,100 years ago. In April 2021, archaeologists announced the discovery of a 1,600-year-old multicolored mosaic dated back to the Byzantine period in an industrial area. According to IAA archaeologist Elie Haddad, it was the first time that excavators revealed a colored mosaic floor in Yavne. The ancient harbour of Yavne, Yavne-Yam (in Arabic Minet Rubin) was identified on the coast. Excavations have revealed fortification going back to the Bronze Age Hyksos. It was in use from the Middle Bronze Age until the 12th century CE, when it was abandoned.
Sources: en.wikipedia.org
It is a 28-residue synthetic peptide studied as an immune-modulating agent and approved as a drug in some countries. The sequence matches a naturally occurring fragment isolated from thymus tissue. It is not a hormone in the endocrine sense.
The name traces back to thymosin fraction 5, a crude thymus extract examined in the 1970s. Individual peptides in that mixture were labeled with Greek letters, and alpha-1 was one of them. The international nonproprietary name thymalfasin was assigned later.
No. Thymosin beta-4 contains 43 residues and binds actin, while thymosin alpha-1 contains 28 residues and acts on immune cells. The two sit in a historical naming group but share no sequence similarity, and they are not substitutes for one another.
Reverse-phase HPLC with ultraviolet detection at 214 nm is common. Mass spectrometry is used to confirm molecular identity and detect modifications. Immunoassays exist but may not distinguish the intact peptide from fragments.